Cemiplimab | m-entrepreneurship.com

Product Name :
Cemiplimab

Search keywords :
Cemiplimab

drugId :
null

Target Vo:
Programmed cell death protein 1

Target Vo Short Name :
PD-1

Moa_Name:
Programmed cell death protein 1 blockers

First Approval Country :
United States

First Approval Date Filter:
2018

Origin Company_Name :
Regeneron Pharmaceuticals Inc

Active Company_Name :
AHS Cancer Control Alberta

Active Indication_Name:
Uterine Cervical Neoplasms

In Active Indication_Name:
HIV Infections

Termination Status :

China Termination Status :

Highest Status:
Approved

China Highest Status:
Phase 3 Clinical

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
Trastuzumab emtansine In Vitro
Ansuvimab Technical Information
ErbB 4 Antibody: ErbB 4 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 147 kDa, targeting to ErbB 4. It can be used for WB assays with tag free, in the background of Human, Rat.

Author: Betaine hydrochloride

Related Posts